Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands. more
Time Frame | NAMS | Sector | S&P500 |
---|---|---|---|
1-Week Return | 1.25% | -2.06% | -0.55% |
1-Month Return | 4.99% | -1.92% | 2.72% |
3-Month Return | 62.32% | -10.4% | 7.66% |
6-Month Return | 51.32% | -4.6% | 10.15% |
1-Year Return | 138.4% | 4.06% | 27.53% |
3-Year Return | 166.36% | 1.94% | 32.31% |
5-Year Return | 139.72% | 36.48% | 89.2% |
Dec '20 | Dec '21 | Dec '22 | Dec '23 | |||
---|---|---|---|---|---|---|
Total Revenue | - | - | 95.91M | 12.76M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":13.31,"profit":true}] | |
Cost of Revenue | - | 14.56K | 70.70K | 44.39K | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":20.59,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":62.79,"profit":true}] | |
Gross Profit | - | (14.56K) | 95.91M | 12.76M | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-0.02,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":13.31,"profit":true}] | |
Gross Margin | - | - | 100.00% | 100.00% | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Expenses | 5.40M | 36.35M | 116.78M | 197.06M | [{"date":"2020-12-31","value":2.74,"profit":true},{"date":"2021-12-31","value":18.45,"profit":true},{"date":"2022-12-31","value":59.26,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | |
Operating Income | (5.43M) | (30.73M) | (3.32M) | (165.73M) | [{"date":"2020-12-31","value":-542900000,"profit":false},{"date":"2021-12-31","value":-3073079200,"profit":false},{"date":"2022-12-31","value":-332188200,"profit":false},{"date":"2023-12-31","value":-16573150800,"profit":false}] | |
Total Non-Operating Income/Expense | (664.00K) | (6.19M) | (17.84M) | 8.91M | [{"date":"2020-12-31","value":-7.45,"profit":false},{"date":"2021-12-31","value":-69.48,"profit":false},{"date":"2022-12-31","value":-200.29,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | |
Pre-Tax Income | (5.75M) | (36.71M) | (21.14M) | (160.25M) | [{"date":"2020-12-31","value":-574900000,"profit":false},{"date":"2021-12-31","value":-3671230100,"profit":false},{"date":"2022-12-31","value":-2113789200,"profit":false},{"date":"2023-12-31","value":-16024507800,"profit":false}] | |
Income Taxes | 344.00K | 216.00K | 70.83M | 27.00K | [{"date":"2020-12-31","value":0.49,"profit":true},{"date":"2021-12-31","value":0.3,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":0.04,"profit":true}] | |
Income After Taxes | (6.09M) | (36.93M) | (91.97M) | (160.27M) | [{"date":"2020-12-31","value":-609300000,"profit":false},{"date":"2021-12-31","value":-3692830100,"profit":false},{"date":"2022-12-31","value":-9196989200,"profit":false},{"date":"2023-12-31","value":-16027207800,"profit":false}] | |
Income From Continuous Operations | (5.75M) | (28.60M) | (78.05M) | (176.94M) | [{"date":"2020-12-31","value":-574900000,"profit":false},{"date":"2021-12-31","value":-2859900000,"profit":false},{"date":"2022-12-31","value":-7805200000,"profit":false},{"date":"2023-12-31","value":-17693700000,"profit":false}] | |
Income From Discontinued Operations | - | - | - | - | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | |
Net Income | (5.75M) | (36.71M) | (21.14M) | (176.94M) | [{"date":"2020-12-31","value":-574900000,"profit":false},{"date":"2021-12-31","value":-3671230100,"profit":false},{"date":"2022-12-31","value":-2113789200,"profit":false},{"date":"2023-12-31","value":-17693700000,"profit":false}] | |
EPS (Diluted) | - | 0.24 | (2.06) | (2.55) | [{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-858.04,"profit":false},{"date":"2023-12-31","value":-1062.21,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
NAMS | |
---|---|
Cash Ratio | 10.25 |
Current Ratio | 10.61 |
Quick Ratio | 10.74 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NAMS | |
---|---|
ROA (LTM) | -29.27% |
ROE (LTM) | -47.37% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NAMS | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.14 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.86 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NAMS | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 78.74 |
P/B | 6.98 |
Price/FCF | NM |
EV/R | 66.17 |
EV/Ebitda | 27.63 |
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) share price today is $25.89
Yes, Indians can buy shares of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) on Vested. To buy NewAmsterdam Pharma Company N.V. Ordinary Shares from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NAMS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) via the Vested app. You can start investing in NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) with a minimum investment of $1.
You can invest in shares of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) via Vested in three simple steps:
The 52-week high price of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is $27.29. The 52-week low price of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is $10.5.
The price-to-earnings (P/E) ratio of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is
The price-to-book (P/B) ratio of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is 6.98
The dividend yield of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is 0.00%
The market capitalization of NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) is $2.29B
The stock symbol (or ticker) of NewAmsterdam Pharma Company N.V. Ordinary Shares is NAMS